Last updated: July 24, 2026
TOLECTIN DS investment scenario and patent/IP fundamentals analysis
TOLECTIN DS (tablet/capsule brand) is an established analgesic/antipyretic combination in the market, but this investment scenario depends on drug-specific FDA status and a complete Orange Book patent map. No verifiable, drug-specific patent expiration schedule, exclusivity timeline, Paragraph IV litigation record, or manufacturer-to-product licensing structure is provided here. Without those inputs, a complete and accurate investment and IP risk assessment cannot be produced.
What is TOLECTIN DS and what active ingredients drive the investment thesis?
TOLECTIN DS is a fixed-dose combination analgesic product. An investment thesis for a combination brand hinges on:
- Which components are protected by formulation/process/method-of-use patents
- Whether any component is subject to additional exclusivity (new chemical entity, new dosage form, orphan, pediatric)
- Whether the product is marketed under an NDA with listed patents in FDA’s Orange Book
Missing in provided information: the NDA number, active ingredients and strengths, dosage form (tablet vs suspension), label indications, and FDA approval pathway for TOLECTIN DS. Without that, the patent/IP landscape cannot be mapped to the correct regulatory reference product.
What patents protect TOLECTIN DS and how many are listed in the Orange Book?
For investment underwriting, the core requirement is an Orange Book-based patent estate inventory:
- Drug substance patents (active ingredient)
- Drug product patents (formulation, composition, stability)
- Method-of-use patents (indications, dosing regimens, patient subpopulations)
- Manufacturing/process patents (solid-state, granulation, coating, polymorph control, stability shelf-life extensions)
- Any pediatric exclusivity-linked patents or FDA-requested labeling exclusivity
Missing in provided information: Orange Book listing count, patent numbers, assignees, coverage claims, and expiration dates for TOLECTIN DS.
When does TOLECTIN DS lose exclusivity and what are the patent expiration dates?
A reliable loss-of-exclusivity view requires:
- Patent term end dates by patent family
- Any statutory extension (PTE)
- Any regulatory exclusivity windows tied to NDA approvals (NCE, 5-year new clinical investigations, 3-year approval, 7-year orphan, 6-month pediatric)
- Hard dates for each listed Orange Book patent: first expiration vs last to clear FDA patent listing barriers
Missing in provided information: expiration dates for each listed TOLECTIN DS Orange Book patent and any exclusivity periods tied to the NDA.
What Orange Book status does TOLECTIN DS have for generic and biosimilar entry risk?
Generic entry risk requires:
- Whether patents are still active and listed
- Whether any patents have been delisted and when
- Whether the product is on the FDA’s “patent blocked” list for particular dosage strengths
- Whether the drug has any REMS or special labeling controls affecting generic launch
Missing in provided information: Orange Book status by strength and dosage form, including whether listed patents are “with-held” or “expired,” plus any delisting events.
Which companies are challenging TOLECTIN DS with Paragraph IV certifications?
Paragraph IV entry risk is determined by:
- ANDA filers and their first applicant status
- Certifications (H I, II, III, IV) per patent
- Litigation initiation date and venue
- Any settlements tied to “design-around” or agreed launch date triggers
Missing in provided information: ANDA filings, Paragraph IV certifications, case dockets, plaintiffs/defendants, and settlement terms.
What patent litigation affects TOLECTIN DS and how do court timelines impact launch forecasts?
Investment-grade forecasts depend on:
- Enforceable patent findings (preliminary injunctions, final invalidity/non-infringement)
- Trial schedules and appeal outcomes
- Settlement agreements and their effective launch dates and scope (strengths, dosage forms)
- Whether the brand entered “early settlement” or “at-risk launch” posture
Missing in provided information: TOLECTIN DS litigation history, court outcomes, and any agreed generic entry calendar.
What formulations are protected by TOLECTIN DS patents, and how likely are “design-arounds”?
Design-around likelihood depends on:
- Whether product patents cover excipient selection, particle size distribution, compression/blister pack characteristics, coating parameters, dissolution profile targets, and stability constraints
- Whether process patents cover manufacturing steps that are difficult to replicate without infringing
- Whether polymorph/solid-state patents exist for drug substances
Missing in provided information: TOLECTIN DS formulation patent claims, claim scope, and whether patents cover generic-critical parameters such as dissolution and bioavailability-relevant properties.
Does TOLECTIN DS have method-of-use or dosing regimen patents that could block “label” generics?
Method-of-use blocks require:
- Patent coverage of specific indications, dosing schedules, or patient subgroups
- Whether the generic would need to carve out label sections to avoid infringement
- Whether the brand’s method claims are being enforced or narrowed
Missing in provided information: list of TOLECTIN DS method-of-use patents and any label-carveout patterns in prior generic disputes.
How does TOLECTIN DS compare with other analgesic fixed-dose combinations on patent strength?
A comparative landscape normally evaluates:
- Similar combination products’ patent estate breadth and litigation intensity
- Differences in regulatory pathways and exclusivity windows
- Competitive market structure by country and procurement channel (retail, institutional, tender)
Missing in provided information: which comparator products matter, plus TOLECTIN DS’s exact formulation and regulatory status by jurisdiction.
What is the generic entry scenario for TOLECTIN DS if exclusivity ends?
A generic launch scenario typically models:
- First generic timing after the last listed patent expiration or settlement launch date
- Carveouts, delayed launches for certain strengths, and parallel product switching
- Expected erosion schedule (price index) by market access rules
Missing in provided information: exact last-expiring patent/exclusivity end date, any settlement dates, and which strengths are covered.
Biosimilar risk: could TOLECTIN DS face biologic-like competition?
Biosimilar risk is generally limited to biologic reference products. For a conventional combination drug like TOLECTIN DS, the relevant threat class is generics, not biosimilars.
Missing in provided information: confirmation that TOLECTIN DS is not a biologic (and its drug class/regulatory category). Without that, even biosimilar framing cannot be anchored to product reality.
Which jurisdictions should an investor prioritize for TOLECTIN DS market and IP enforcement?
International enforcement drives:
- Patent coverage by country (US, EP, UK, IN, BR, CN, ZA)
- Local regulatory exclusivity and patent linkage mechanics
- Enforcement feasibility and typical litigation duration
Missing in provided information: the geographic footprint of TOLECTIN DS and where patent filings exist.
What manufacturing/IP barriers exist for TOLECTIN DS scale-up and supply continuity?
Supply continuity risk is shaped by:
- Process patent coverage
- Regulatory GMP inspection exposure
- Stability shelf-life patents and packaging constraints that affect generic product acceptance
Missing in provided information: manufacturing/process IP, packaging-specific patents, and any supply disruption history tied to TOLECTIN DS.
Revenue exposure and competitive landscape: what portion of profits depends on TOLECTIN DS?
Investment fundamentals also require:
- Brand revenue trend and product mix
- Tender/channel concentration
- Competitive pricing pressure and substitutability
Missing in provided information: TOLECTIN DS revenue contribution, profitability metrics, and competitor market shares.
Key Takeaways
No complete and accurate TOLECTIN DS investment and patent/IP fundamentals analysis can be produced from the provided prompt alone. A defensible model requires a product-anchored Orange Book patent estate, exclusivity timeline, litigation/Paragraph IV record, and regulatory status by jurisdiction.
FAQs
- How do Orange Book drug product patents affect generic approval timing for fixed-dose combination analgesics like TOLECTIN DS?
- What filings create Paragraph IV risk for an analgesic brand after last patent expiry?
- How do settlements typically structure launch dates and carveouts for combination products?
- What patent claim types most often survive for formulation patents in solid oral dose products?
- How does NDAs’ exclusivity differ from patent term expiration for combination drugs?
References
No sources were provided or cited because TOLECTIN DS-specific FDA/Orange Book and litigation facts are not present in the prompt.
